The CSF-1R inhibitor pexidartinib shrank tumor size and improved symptoms in patients with tenosynovial giant cell tumor (TGCT), with encouraging results in the phase III clinical study (NCT02371369) of CSF1/CSF1R-targeted therapy for benign diffuse TGCT [186]. The gene discussed is CSF1; the disease is tenosynovial giant cell tumor.